Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of the Efficacy of a Herbal Supplement in the Prevention of Treatment of Post-traumatic Stress Disorder Versus Placebo (PHYTéS Study)
Brief Summary: Psycho-traumatic disorders are a disabling condition whose epidemiological data vary according to the country but also the populations studied and the measuring instruments used. The estimated prevalence of posttraumatic stress disorder (PTSD) appeared to be increasing in recent years, and this appears to be due, among other things, to the improvement of the standardized evaluation procedure. The survey "Mental Health in General Population", conducted in metropolitan France between 1999 and 2003 on more than 36,000 people estimated its instantaneous prevalence (last month) of a full PTSD was 0.7% in the SMPG overall sample, with almost equal frequency between men (45%) and women (55%). This figure is close to that reported in a European population for the ESEMeD study. A very significant psychiatric comorbidity was found in subjects with PTSD, particularly with mood disorders, other anxiety disorders and addictive behaviors. The link with the suicidal risk was clearly established, which is the gravity of this pathology.

The most important publications are made by American teams who have identified and evaluated the treatment of this pathology among veterans of the various wars led by the country.


Options:
A: Inclusion Criteria:

* Female patients between the ages of 18 years and 50 years
* Victim of sexual assault/rape
* Able to understand consent procedure
* Discharged to home

Exclusion Criteria:

* Admitted to inpatient unit
* Previous diagnosis of PTSD
* Contra-indications to prazosin: orthostatic hypotension, right heart failure, use of anti-hypertensive medication, 5-phosphodiesterase inhibitors (sildenafil) or diuretic, history of syncope or severe unexplained faintness, known hypersensitivity to quinazolines
* Hemodynamically unstable
* Current use of over the counter, prescribed, or use of other drugs for insomnia
* Dependence on alcohol, opiates or other illegal drugs
* History of psychotic disorder
* Suicidal risk defined by a positive response on the 3-item assessment, standard protocol in the ED
* Current use of morphine or methadone
* Pregnant or breastfeeding
* Known hepatic dysfunction
* Cardiac or vascular history including coronary artery disease
* Narcolepsy
* History of sleep apnea
* Returning to chronic domestic abuse situation
B: Inclusion Criteria for All Participants:

* Able to give informed consent
* Physically and neurologically healthy \[confirmed by a comprehensive medical history\]
* Age between 21-45 years old
* Right-handed

Inclusion Criteria for Participants with PTSD:

* Current PTSD diagnosis \[related to civilian trauma\]

Inclusion Criteria for Trauma-Exposed Participants without PTSD:

* Experience with a civilian trauma without a PTSD diagnosis
* Free of a lifetime Axis I or Axis II diagnosis

Inclusion Criteria for Non-Trauma-Exposed Healthy Participants:

* Free of a lifetime Axis I or Axis II diagnosis

Exclusion Criteria for All Participants:

* Clinically significant medical or neurological condition
* Less than a high school education
* Lack of fluency in English
* Night shift work
* Currently pregnant; planning pregnancy; or lactating
* Unwilling/unable to sign informed consent document
* Inability to tolerate small, enclosed spaces without anxiety (e.g. claustrophobia)
* Left-handed
* Presence of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)
* Under 21 or over 45 years of age
* Anticipation of a required drug test in the 4 weeks following study participation
* Positive urine drug screen and/or alcohol breathalyzer
* Current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances \[dronabinol/marijuana/cannabis/thc, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide\]
* Participation in an experiment involving white noise bursts or shocks in the last 6 months

Exclusion Criteria for Participants with PTSD:

* Primary comorbid anxiety disorder (defined by which disorder was the more debilitating and clinically salient)
* Life history of bipolar disorder, schizophrenia, or presence of an organic mental syndrome, mental retardation, or pervasive developmental disorder
* Current or in the past 6 months alcohol/drug abuse of dependence
* Current or in the past 6 months major depressive disorder
* Current suicidal ideation
* Diagnosis of an Axis II personality disorder
* Concomitant treatments with psychotropic/psychoactive medication \[including beta-adrenergic blockers, selective serotonin reuptake inhibitor (SSRI), benzodiazepines, tricyclic or monoamine oxidase inhibitor (MAOI) antidepressants, lithium, antiepileptic/anticonvulsants, neuroleptics/antipsychotics, etc.) or in the past two weeks \[8 weeks for fluoxetine and 4 weeks for MAOIs) before screening (Visit 1)
* currently receiving exposure-based therapy for PTSD

Exclusion Criteria for Trauma-Exposed Participants without PTSD and Non-Trauma Exposed Healthy Participants:

* Current or past Axis I psychiatric disorder \[including alcohol/substance abuse of dependence disorder\]
C: Inclusion Criteria:

* Any patient who has been exposed to a traumatic event that could cause an acute PTSD (accident or aggression that causes intense fear, helplessness or horror)
* a PDI (Peri-traumatic Distress Inventory) score and / or PDEQ (Traumatic Traumatic Dissociation Experience Questionnaire - Evaluative Form)
* and / or (Appendix 1, 2 and 3) calculated between J1 and J3 and estimated moderate or high with a score\> 15.

Exclusion Criteria:

* Any serious traumatized patient who needed treatment in intensive care.
* Any patient with psychiatric illness or psychotropic medication prior to randomization.
* Non-cooperating patient (unable to answer the assessment test).
* Non consenting patient.
D: Inclusion Criteria:

1. Clinical evidence of infection within the previous 72 hours (may be present longer than 72 hours) (a, b, c, or d - only 1 required)

   1. Presence of polymorphonuclear cells in a normally sterile body fluid (excluding blood);
   2. Culture or Gram stain of blood, sputum, urine or normally sterile body fluid positive for a pathogenic micro-organism;
   3. Focus of infection identified by visual inspection (e.g. ruptured bowel with the presence of free air or bowel contents in the abdomen found at the time of surgery, wound with purulent drainage);
   4. Other clinical evidence of infection - treated community acquired pneumonia, purpura fulminans, necrotising fascitis, etc.
2. Evidence of a systemic response to infection as defined by the presence of two or more of the following signs within the previous 24 hours. These signs may be present longer than 72 hours.

   1. Fever (temperature \>38.3°C) or hypothermia (rectal temperature \< 35.6°C);
   2. Tachycardia (heart rate of \>90 beat/min);
   3. Tachypnea (respiratory rate \> 20 breaths/min, PaC02\<32 mmHg) or patient requires invasive mechanical ventilation;
   4. Alteration of the WBC count \>12,000 cells/mm3, \<4,000 cells/mm3 or \>10% immature neutrophils (bands).
3. Evidence of shock defined by (A + B- both required within the previous 72 hours (may NOT be present longer than 72 hours).

A. A systolic blood pressure \< 90 mmHg or a decrease in SBP of more than 50 mmHg from baseline in previous hypertensive patients (for at least one hour) despite adequate fluid replacement OR need for vasopressors for at least one hour (infusion of dopamine ≥ 5 mcg/kg/min or any dose of adrenaline, noradrenaline, phenylephrine or vasopressin) to maintain a SBP ≥ 90 mmHg;

B. Hypoperfusion or organ dysfunction which is not the result of underlying diseases or drugs, but is attributable to sepsis, including one of the following:

1. Sustained oliguria (urine output \< 0.5 ml/kg/hr for a minimum of 1 hour)
2. Metabolic acidosis \[pH of \< 7.3, or a base deficit of \> or = 5.0 mmol/L, or an increased lactic acid concentration (\> 2 mmol/L)\].
3. Arterial hypoxemia (Pa02/FI02\<280 in the absence of pneumonia)(Pa02/FI02\<200 in the presence of pneumonia).
4. Thrombocytopenia - platelet count ≤ 100,000 cells/mm3.
5. Acute altered mental status (Glasgow Coma Scale \< 14 or acute change from baseline).

4. Informed Consent

5. Cortisol level at baseline and 60 minutes after 0.25 mg cosyntropin

Exclusion Criteria:

1. Pregnancy
2. Age less than 18.
3. Underlying disease with a prognosis for survival of less than 3 months.
4. Cardiopulmonary resuscitation within 72 hours before study.
5. Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4 weeks before the study.
6. Administration of chronic corticosteroids in the last 6 months or acute steroid therapy (any dose) within 4 weeks (including inhaled steroids). Topical steroids are not exclusions.
7. HIV positivity.
8. Presence of an advanced directive to withhold or withdraw life sustaining treatment (i.e. DNR).
9. Advanced cancer with a life expectancy less than 3 months.
10. Acute myocardial infarction or pulmonary embolus.
11. Another experimental drug study within the last 30 days.
12. Moribund patients likely to die within 24 hours.
13. Patients in the ICU for more than 2 months at the time of the start of septic shock.

Answer: C